Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression

Biochemical and Biophysical Research Communications

Volumn 413, Issue 1, 2011, Pages 62-68

  Katsumi, Yoshiki ^a   Iehara, Tomoko ^a   Miyachi, Mitsuru ^a   Yagyu, Shigeki ^a   Tsubai Shimizu, Satoko ^a   Kikuchi, Ken ^a   Tamura, Shinichi ^a   Kuwahara, Yasumichi ^a   Tsuchiya, Kunihiko ^a   Kuroda, Hiroshi ^a   Sugimoto, Tohru ^a   Houghton, Peter J ^b   Hosoi, Hajime ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

CDK4; INI1; P16; PD 0332991; Rhabdoid tumor

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; CYCLIN DEPENDENT KINASE 4; PROTEIN P16; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IC 50; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RHABDOID TUMOR; STATISTICAL SIGNIFICANCE; TUMOR CELL LINE;

CELL LINE, TUMOR; CHILD; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; DRUG RESISTANCE, NEOPLASM; HELA CELLS; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; RHABDOID TUMOR;

EID: 80052850363     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.08.047     Document Type: Article

References (24)

1. Versteege I., Sévenet N., Lange J., et al. Truncating mutations of hSNF5/INI1in aggressive paediatric cancer. Nature 1998, 394:203-206.
2. Tomlinson G.E., Breslow N.E., Dome J. Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: age at diagnosis as a prognostic factor. J. Clin. Oncol. 2005, 23:7641-7645.
3. Zhang Z.K., Davies K.P., Allen J., et al. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol. Cell. Biol. 2002, 22:5975-5988.
4. Oruetxebarria I., Venturini F., Kekarainen T., et al. p16 is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells. J. Biol. Chem. 2004, 279:3807-3816.
5. Imbalzano A.N., Jones S.N. Snf5 tumor suppressor couples chromatin remodeling, Checkpoint control, and chromosomal stability. Cancer Cell 2005, 7:294-295.
6. Fry D.W., Harvey P.J., Keller P.R., et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 2004, 3:1427-1438.
7. Dean J.L., Thangavel C., McClendon A.K., Reed C.A., Knudsen E.S. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010, 29:4018-4032.
8. Finn R.S., Dering J., Conklin D., et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009, 11:R77.
9. Saab R., Bills J.L., Miceli A.P., et al. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol. Cancer Ther. 2006, 5:1299-1308.
10. Baughn L.B., Di Liberto M., Wu K., et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 2006, 66:7661-7667.
11. Marzec M., Kasprzycka M., Lai R., et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 2006, 108:1744-1750.
12. Michaud K., Solomon D.A., Oermann E., et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 2010, 70:3228-3238.
13. Sugimoto T., Hosoi H., Horii Y., et al. Malignant rhabdoid-tumor cell line showing neural and smooth-muscle-cell phenotypes. Int. J. Cancer 1999, 82:678-686.
14. Wang L., Wang J., Blaser B.W., et al. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 2007, 110:2075-2083.
15. Tamura S., Hosoi H., Kuwahara Y., et al. Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells. Biochem. Biophys. Res. Commun. 2007, 358:226-232.
16. Tsuchiya K., Hosoi H., Misawa-Furihata A., Houghton P.J., Sugimoto T. Insulin-like growth factor-I has different effects on myogenin induction and cell cycle progression in human alveolar and embryonal rhabdomyosarcoma cells. Int. J. Oncol. 2007, 31:41-47.
17. Kuwahara Y., Hosoi H., Osone S., et al. Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo. Clin. Cancer Res. 2004, 10:5940-5948.
18. Kikuchi K., Tsuchiya K., Otabe O., et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem. Biophys. Res. Commun. 2008, 365:568-574.
19. van Nes J.G., Smit V.T., Putter H., et al. Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients. Br. J. Cancer 2009, 100:494-500.
20. Tsikitis M., Zhang Z., Edelman W., Zagzag D., Kalpana G.V. Genetic ablation of cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. Proc. Natl. Acad. Sci. USA 2005, 102:12129-12134.
21. Kuwahara Y., Charboneau A., Knudsen E.S., Weissman B.E. Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism. Cancer Res. 2010, 70:1854-1865.
22. Katsumi Y., Kuwahara Y., Tamura S., et al. Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity. Clin. Cancer Res. 2008, 14:1192-1199.
23. Kia S.K., Gorski M.M., Giannakopoulos S., Verrijzer C.P. SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol. Cell. Biol. 2008, 28:3457-3464.
24. Jacobs J.J., Kieboom K., Marino S., DePinho R.A., van Lohuizen M. The oncogene and polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397:164-168.